<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Barata P</submitter><funding>NA</funding><funding>NCI NIH HHS</funding><pagination>e178915</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11142736</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>134(11)</volume><pubmed_abstract>Molecular profiling of clear cell renal cell carcinoma (ccRCC) tumors of patients in a clinical trial has identified distinct transcriptomic signatures with predictive value, yet data in non-clear cell variants (nccRCC) are lacking. We examined the transcriptional profiles of RCC tumors representing key molecular pathways, from a multi-institutional, real-world patient cohort, including ccRCC and centrally reviewed nccRCC samples. ccRCC had increased angiogenesis signature scores compared with the heterogeneous group of nccRCC tumors, while cell cycle, fatty acid oxidation/AMPK signaling, and fatty acid synthesis/pentose phosphate signature scores were increased in one or more nccRCC subtypes. Among both ccRCC and nccRCC tumors, T effector scores statistically correlated with increased immune cell infiltration and were more commonly associated with immunotherapy-related markers (PD-L1+/TMBhi/MSIhi). In conclusion, this study provides evidence of differential gene transcriptional profiles among ccRCC versus nccRCC tumors, providing insights for optimizing personalized and histology-specific therapeutic strategies for patients with advanced RCC.</pubmed_abstract><journal>The Journal of clinical investigation</journal><pubmed_title>Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.</pubmed_title><pmcid>PMC11142736</pmcid><funding_grant_id>K08 CA273542</funding_grant_id><funding_grant_id>NA</funding_grant_id><pubmed_authors>Geynisman DM</pubmed_authors><pubmed_authors>Hammers HJ</pubmed_authors><pubmed_authors>Dawson NA</pubmed_authors><pubmed_authors>Gulati S</pubmed_authors><pubmed_authors>Basu A</pubmed_authors><pubmed_authors>Heath EI</pubmed_authors><pubmed_authors>Bilen MA</pubmed_authors><pubmed_authors>Poorman KA</pubmed_authors><pubmed_authors>Ryan CJ</pubmed_authors><pubmed_authors>Zhang T</pubmed_authors><pubmed_authors>Nabhan C</pubmed_authors><pubmed_authors>Barata P</pubmed_authors><pubmed_authors>Gartrell BA</pubmed_authors><pubmed_authors>Wei S</pubmed_authors><pubmed_authors>Elliott A</pubmed_authors><pubmed_authors>Burgess E</pubmed_authors><pubmed_authors>McKay RR</pubmed_authors><pubmed_authors>Darabi S</pubmed_authors><pubmed_authors>Zibelman MR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.</name><description>Molecular profiling of clear cell renal cell carcinoma (ccRCC) tumors of patients in a clinical trial has identified distinct transcriptomic signatures with predictive value, yet data in non-clear cell variants (nccRCC) are lacking. We examined the transcriptional profiles of RCC tumors representing key molecular pathways, from a multi-institutional, real-world patient cohort, including ccRCC and centrally reviewed nccRCC samples. ccRCC had increased angiogenesis signature scores compared with the heterogeneous group of nccRCC tumors, while cell cycle, fatty acid oxidation/AMPK signaling, and fatty acid synthesis/pentose phosphate signature scores were increased in one or more nccRCC subtypes. Among both ccRCC and nccRCC tumors, T effector scores statistically correlated with increased immune cell infiltration and were more commonly associated with immunotherapy-related markers (PD-L1+/TMBhi/MSIhi). In conclusion, this study provides evidence of differential gene transcriptional profiles among ccRCC versus nccRCC tumors, providing insights for optimizing personalized and histology-specific therapeutic strategies for patients with advanced RCC.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-04-29T14:07:03.484Z</modification><creation>2026-04-07T15:15:18.906Z</creation></dates><accession>S-EPMC11142736</accession><cross_references><pubmed>38652565</pubmed><doi>10.1172/JCI178915</doi></cross_references></HashMap>